| Overview |
| bsm-90307R |
| PI3 Kinase p110 beta Recombinant Antbody Kit (KD-Validated) |
| WB, FCM |
| Knockdown Validated |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthesized peptide derived from human PI3 Kinase p110 beta |
| 5-22/1070 |
| Monoclonal |
| IgG |
| Lot dependent |
| Affinity Purified |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| -20 °C |
| Target |
| 5291 |
| P42338 |
| Phosphatidylinositol-45-Bisphosphate 3-Kinase; Catalytic SubunitBeta; PI3K; PIK3C1; PI3KBETA; Phosphoinositide-3-Kinase; Catalytic; Beta Polypeptide; Phosphatidylinositol 45-Bisphosphate 3-Kinase Catalytic Subunit Beta Isoform; Phosphatidylinositol 45-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Beta; Phosphatidylinositol-45-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Beta; PtdIns-3-Kinase Subunit Beta; PI3-Kinase P110 Subunit Beta; PtdIns-3-Kinase Subunit P110-Beta; PtdIns-3-Kinase P110; PI3K-beta; PI3Kbeta; PI3-Kinase Subunit Beta; p110beta; EC 2.7.1.153; PI3KCB; P110BETA; EC 2.7.1 |
| Cell Line: HT-1080 Knockdown technology: shRNA Knockdown |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz